AngioDynamics (NASDAQ:ANGO) Issues FY 2026 Earnings Guidance

Key Points

• AngioDynamics has updated its FY 2026 earnings guidance, projecting an EPS of -0.330 to -0.230 and revenue of $308.0 million to $313.0 million, both slightly above analysts' consensus estimates.
• Analysts are optimistic about AngioDynamics, with three rating the stock as a "buy" and price targets ranging up to $24.00, reinforcing a consensus price target of $19.00.
• The company's recent quarterly results showed a revenue increase of 12.1% year-over-year, with reported earnings of ($0.10) per share, outperforming expectations.

AngioDynamics (NASDAQ:ANGO - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of -0.330--0.230 for the period, compared to the consensus EPS estimate of -0.310. The company issued revenue guidance of $308.0 million-$313.0 million, compared to the consensus revenue estimate of $306.9 million.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wall Street Zen raised AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of AngioDynamics in a research note on Wednesday, July 16th. Canaccord Genuity Group upped their price objective on shares of AngioDynamics from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. Finally, Lake Street Capital assumed coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 target price on the stock. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $19.00.

AngioDynamics Price Performance

NASDAQ:ANGO opened at $11.07 on Thursday. AngioDynamics has a one year low of $5.83 and a one year high of $13.50. The firm's 50 day simple moving average is $9.84 and its 200 day simple moving average is $9.73. The company has a market cap of $454.76 million, a PE ratio of -13.34 and a beta of 0.78.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The company had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. During the same quarter in the previous year, the business earned ($0.11) earnings per share. AngioDynamics's revenue was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. Equities research analysts expect that AngioDynamics will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ANGO. Arrowstreet Capital Limited Partnership increased its position in shares of AngioDynamics by 8.1% during the second quarter. Arrowstreet Capital Limited Partnership now owns 583,675 shares of the medical instruments supplier's stock worth $5,790,000 after buying an additional 43,573 shares during the period. Manatuck Hill Partners LLC boosted its position in AngioDynamics by 7.7% during the second quarter. Manatuck Hill Partners LLC now owns 350,000 shares of the medical instruments supplier's stock valued at $3,472,000 after acquiring an additional 25,000 shares during the last quarter. Bank of America Corp DE grew its holdings in AngioDynamics by 729.4% during the 2nd quarter. Bank of America Corp DE now owns 286,208 shares of the medical instruments supplier's stock worth $2,839,000 after acquiring an additional 251,702 shares during the period. Goldman Sachs Group Inc. raised its position in shares of AngioDynamics by 9.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier's stock worth $2,434,000 after acquiring an additional 22,658 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of AngioDynamics by 2.2% in the 2nd quarter. Invesco Ltd. now owns 122,596 shares of the medical instruments supplier's stock valued at $1,216,000 after purchasing an additional 2,667 shares during the period. Institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.